Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest

Fig. 1

Workflow for AR, AR-V7, PSMA, and PSA AdnaTest applied to exosomal cfRNA and VTX-1-isolated CTCs. Blood was collected from patients with mCRPC and resistance to ARI inhibitors. Plasma was extracted from whole blood by centrifugation. (A) Exosomal cfRNA was extracted from plasma exosomes using exoRNeasy Serum Plasma Kit (QIAGEN). (B) CTCs were isolated from the plasma-depleted blood with VTX-1 and lysed using the Adna lysis/binding buffer. (C) CTC lysate and exosomal cfRNA were assayed for expression of AR, AR-V7, PSMA, and PSA mRNA with AdnaDetect. (D) A separate tube of whole blood was processed with VTX-1 in parallel for CTCs enumeration. mCRPC: metastatic castration-resistant prostate cancer; CTC: circulating tumor cell; mRNA: messenger RNA; AR: androgen receptor; AR-V7: AR splice variant 7; PSMA: prostate-specific membrane antigen; PSA: prostate-specific antigen; cfRNA: cell-free RNA

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us